Sales of non-insulin treatments for diabetes helped sustain growth at Novo Nordisk A/S where turnover for 2019 amounted to DKK 122 billion (€16.3 billion), up by 9% on a reported basis from a year earlier and by 6% in constant exchange rates. Operating profit advanced by 11% to DKK 52.3 billion giving an operating margin of 43%.
Sales, distribution and administration costs increased during the year however spending on research and development declined partly due to a reversal of write-downs of inventory prior to the launch of the oral semaglutide drug Rybelsus.